Sie befinden sich hier

Inhalt

Curriculum Vitae

Prof. Dr. med. Heike Allgayer, MD, PhD

*12. June 1969 in Lindenberg/Allgäu, Germany

Main Research Fields

  • Metastasis research
  • microRNAs in metastasis
  • Tumor-associated proteolysis
  • Translational metastasis research
  • Molecular staging of cancer and metastasis

Education/Training

1995
Final Medical Board Examination (MD), Medicine, Ludwig-Maximilians-University Munich

1996
Dr. med. (Medicine, Translational Research) Ludwig-Maximilians-University Munich, with “summa cum laude”

1997 - 1999
Postdoctoral Fellow (Molecular Biology, Metastasis), MD Anderson Cancer Center, Houston/USA

1999
PhD, Molecular Biology, Graduate School of Biomedical Sciences (GSBS), MD Anderson Cancer Center, Houston/USA

1999 - 2001
Assistant Professor, Section Molecular Biology, Dept. Surgery, Clinical Surgeon, Surgical Oncology, Ludwig-Maximilians-University Munich

2001
Priv.Doz. (Associate Professor), Experimental Surgery/Molecular Biology, Ludwig-Maximilians-University Munich

2003
Diploma in Medical Economics, Chur, Switzerland

2004
Surgical Board Exam, Munich/Germany

2004 - 2015
Full Professor and Head, Dept. of Experimental Surgery, Med. Faculty Mannheim, Univ. of Heidelberg, Molecular Oncology of Solid Tumors Unit, DKFZ Heidelberg, Germany

Since 2015
Full Professor and Director, Dept. of Experimental Surgery - Cancer Metastasis, Centre for Biomedicine and Medical Technology Mannheim (CBTM), Med. Faculty Mannheim, University of Heidelberg

2018 - 2020
Vice Director, Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg

Positions and Employment

Positions and Employment

1996 - 1997
Medical Intern, Dept. Surgery, Klinikum Großhadern, Ludwig-Maximilians-University Munich

1997 – 1999
Fellow at the Dept. of Cancer Biology, MD Anderson Cancer Center, Houston,TX (Prof. Douglas D. Boyd, PhD, Principal Investigator, Prof. J.I. Fidler, Head)

1999 – 2004
Assistant, later Associate Professor, Molecular Oncology, PI of section Molecular Biology, in parallel: Resident, Dept. of Surgery, Klinikum Großhadern, Ludwig-Maximilians-University Munich

2004 - 2015
Full Professor and Head, Dept. Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg, and Adjunct Professor, DKFZ (German Cancer Research Center) Heidelberg

Since 2015
Full Professor and Director, Dept. of Experimental Surgery – Cancer Metastasis, Medical Faculty Mannheim, University of Heidelberg

2018 - 2020
Vice Director, Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg

Professional Memberships

1995
Vereinigung der Bayerischen Chirurgen

1998
Active/Corresponding Member der American Association of Cancer Research (AACR)

1999
Deutsche Gesellschaft für Chirurgie

1999
Molekularbiologische Arbeitsgemeinschaft der Deutschen Gesellschaft für Chirurgie (CAMO)

2003
Berufsverband der Deutschen Chirurgen (BDC)

2005
European Association of Cancer Research (EACR)

2006
American Society of Clinical Oncology (ASCO)

2007
EACR Council Member, Member of Communications Committee

2007
Member of  EORTC Pathobiology Group

2010
Deutsche Gesellschaft für Stammzellforschung

2011
Metastasis Research Society

2012
Academia.Net of the Robert Bosch Foundation

2013
Task Force „Surgical Oncology“, American Association for Cancer Research (AACR)

2014
European Society for Translational Medicine (EUSTM)

2014
Invited Member, WORLD.MINDS, Zurich

2016
EORTC Translational Research Advisory Committee (EORTC-TRAC; chair: Emilie Varin)

2017
Elected Member of the EACS Fellowship of the European Academy of Cancer Sciences

2019
Invited Member, EACR Conference Series Committee

Honors/Awards

Excerpt out of a total of 23 awards

1986
1st Prize of the German Chemical Industry for the promotion of research youngsters

1997
Research fellowship of the Dr. Mildred Scheel Stiftung (Deutsche Krebshilfe), Bonn, Germany, for postdoctoral period, MD Anderson Cancer Center, Houston

1999
Rhone-Poulenc-Rorer-Award for Young Investigators of the American Association of Cancer Research (AACR), Philadelphia, USA

1999
Langenbeck Research Award of the German College of Surgeons

1999
1st Prize, Wolfgang Wilmanns Research Foundation for Innovative Concepts of Translational Cancer Research

2000
Otto-Goetze-Award for the best scientific lecture at the Year 2000-Congress of the Bavarian College of Surgeons

2000
1st Prize of the DPC-Biermann-Academy of Biomedical Sciences

2001
Ferdinand-Sauerbruch Research Award of the Berlin College of Surgeons

2002
Johann-Nepomuk-von-Nussbaum-Research Award of the Bavarian College of Surgeons

2002
Research Award of the Drs. Graute- und Graute-Oppermann-Foundation, Essen

2003
Johann-Georg-Zimmermann-Award for Extraordinary Merits in Cancer Research, University of Hannover

2003
Travel Award of the Japanese Society of Surgery

2004
Research Award of the Ingrid-zu-Solms Foundation for excellent achievements of Women in Science, Frankfurt, Germany

2005
Young Cancer Researcher Award Lecture of the EACR (European Association of Cancer Research)

2005
Research Award for high-potential young Full Professors, Alfried Krupp von Bohlen- and Halbach-Foundation, Essen, Germany (1 Mill. Euro, the second highest and most competitive Research Award in Germany)

2006
Hella-Bühler-Award, University of Heidelberg, Germany

2007
European Association for Cancer Research (EACR) First Annual Distinguished Lecture, Nottingham, UK

2008
Walter-Schulz Award, Munich, Germany

2013
Annual Lilly Oncology Lecture, Dresden 2013

2014/15
Inoviem Scientific Excellence Award, Inoviem Scientific, Strasbourg

2020/21
Otto Herz Memorial Lecture in Cancer Research at University of Tel Aviv, Israel (previous lecturers: e.g., Robert Gallo (1982), Harald zur Hausen (1984), Howard Temin (1985), Hilary Koprowski (1986), Isaiah Fidler (1990), David Goldenberg (1991), Judah Folkman (1994), Charles Weissmann (1996), Fritz Melchers (1997), Harold L. Moses (1998), Carlo M. Croce (1999), Richard D. Klausner (2000), Alberto Mantovani (2003), Zena Werb (2005))                                                                                                  

Patent

Allgayer H, Leupold JH (2003): Tissue specific expression (PCT/EPO3/01671)

Publications

Ca. 300; ca. 100 of these Original Articles

Total Impact Factor according to current IF directory (2019/2020; all publications incl. Reviews etc.): ca. 1000

  • The top original articles have been published in: Nature Medicine, Nature Communications, Cancer Research, Journal of Clinical Oncology, Oncogene, and Clinical Cancer Research.
  • Most cited original article as Senior Author: Asangani I et al., Oncogene 2009 (currently 1985 citations according to Google Scholar, most cited original article of Oncogene 2009)

 

Examples of publications:

Ishaque N, Abba ML, Hauser C, Patil N, Paramasivam N, Huebschmann D, Leupold JH, Balasubramanian GP, Kleinheinz K, Toprak UH, Hutter B, Benner A, Shavinskaya A, Zhou C, Gu Z, Kerssemakers J, Marx A, Moniuszko M, Kozlowski M, Reszec J, Niklinski J, Eils J, Schlesner M, Eils R, Brors B, and Allgayer H: Whole genome sequencing reveals novel hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications 2018, Nov 14;9(1):4782. doi: 10.1038/s41467-018-07041-z

Allgayer H, Leupold JH, Patil N. Defining the "Metastasome": Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences (Invited Review). Semin Cancer Biol. 2019 Jul 27. pii: S1044-579X(19)30156-7. doi: 10.1016/j.semcancer.2019.07.018. Review. PMID: 31362074

Mudduluru G*, Abba M*, Batliner J*,Patil N, Scharp M, Leupold JH, Oleksiuk O, Buchhalter I, Thiele W, Benner A,  Sleeman J, Allgayer H:: A systematic approach to defining the microRNA landscape in metastasis. Cancer Research 2015, Aug 1; 75(15):3010-9. doi: 10.1158/0008-5472.CAN-15-0997. Epub 2015 Jun 11.

Utikal J, Abba M, Novak D, Moniuszko M, Allgayer H (Invited Review): Function and Significance of MicroRNAs in benign and malignant Human Stem Cells.  Seminars in Cancer Biology 2015, 35, 200-211.

Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27, 2128-2136 (currently >2000  citations, Most cited Original Article Oncogene 2009, Source: Google Scholar).

Rasheed SAK, Efferth T, Asangani IA, Allgayer H: Artesunate – First evidence that an anti-malaria drug inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127(6):1475-85, 2010.

Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011, 30, 2888-2899 (101 citations).

Nikolova DA, Asangani IA, NelsonLD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H: Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Research 2009, 69, 2461-2470.

Mudduluru G, Medved F, Grobholz R, Joste C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H: Loss of Pdcd4 expression marks adenoma-carcinoma transition, correlates inversely with pAkt, and is a new and independent prognostic factor in resected colorectal cancer. Cancer 2007, 110:8, 1697-1707 (141 citations).

Heiss MM, Simon EH, Beyer BCM, Grützner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H: Minimal residual disease in gastric cancer: First evidence of an independent prognostic relevance of urokinase receptor gene expression by disseminated tumor cells in a large series of patients. The Journal of Clinical Oncology 2002, 20(8):2005-2016 (83 citations ).

Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H: Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007, 26, 4550-62 (116 citations).

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung H-M, Lau-Werner U, Post S, Allgayer H: First analysis of specific transcriptional regulators as predictors of independent prognostic relevance in resected colorectal cancer. Clinical Cancer Research 2007, 13(4): 1123-1132.

Ceppi P, Mudduluru G, Regalla K, Rap I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small-cell lung cancer. Mol Cancer Res  Sept 2010, 8(9): 1207-16 Highlight of the Issue (166 citations).

Mesenguer S, Mudduluru G, Escamilla JM, Allgayer H*, Barrettino D*: MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF).  Journal of Biological Chemistry 2011, 286(6), 4150-4164 (63 citations), *equal senior authorship.

Regalla K, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M, Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer J 2012 May 1;130(9):2044-53 (105 citations).

Heckmann D, Maier P, Laufs S, Li L, Wenz F, Zeller WJ, Fruehauf S, Allgayer H: The disparate twins: A comparative study of CXCR4 and CXCR7 in SDF-1-induced gene expression, invasion and chemosensitivity of colon cancer.  Clin Cancer Res. 2014 Feb 1;20(3):604-16.

Patil N, Rasheed SAK, Abba M, Leupold JH, Schwarzbach M, Allgayer H: A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma Running title: The role of FUS-CHOP in metastasis. Int J Cancer. 2014 Jun 15;134(12):2808-19.

Laudato, S., Patil, N., Abba, M. L., Leupold, J. H., Benner, A., Gaiser, T., Marx, A., Allgayer H: P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30854.

Grant Support

Total direct funding by competitive grant support for the H. Allgayer lab: ca. € 5.15 Mio

Completed grant supports

2004
B. Braun Foundation, Melsungen

2004
Friedrich Baur Foundation, München

2004
Research Funding Centocor, Malvern, USA, “Immunohistochemical and – cytochemical analysis of EMMPRIN and MCP-1 in material of gastrointestinal cancer patients”

2005
Wilhelm Sander Foundation, München, „Molecular Staging Simulation with Neural Networks“, together with Prof. N. Harbeck und Dr. R. Kates, Munich

2005
Auguste Schaedel-Dantscher-Foundation, “Role of Pdcd4 tumor suppressor in invasion”

2005
Merck, Darmstadt „Translational studies at resected patient tissues on Cetuximab response and resistance“

2006
Merck, Darmstadt “Preclinical project: molecular mechanisms of anti-metastasis of Cetuximab”

2006
Deutsche Forschungsgemeinschaft (DFG), „Molecular Staging of Cancer“

2006
National Cancer Institutes, USA, “Defining molecular risk groups in colorectal cancer”

2006
Daub Foundation, University of Heidelberg, “Advancing the chicken embryo (CAM) metastasis model”

2006
Novartis, Nürnberg, “Mechanisms of metastasis inhibition brought about by zoledronic acid”

2006
Eli Lilly, Indianapolis/USA, together with Prof. Christian Manegold, “Preclinical and translational studies on Enzastaurin and is action towards metastasis”

2006
Industrial Grant Support, Congress „Molecular Staging of Cancer“, Eli Lilly, Merck, Novartis, and others

2006
Dr. Hella-Bühler-Foundation, Univ. of Heidelberg, „Molecular regulators of metastasis as individual clinical risk factors“

2007
Hector-Foundation, Weinheim, „Role of CXRC4 in colorectal cancer metastasis and therapy“

2008
Walter-Schulz-Foundation, München, „Studies on microRNAs and Pdcd4 in metastasis“

2008
Excellence Initiative „FRONTIER“, University of Heidelberg, “FUS-CHOP as a regulator of invasion and metastasis in sarcoma”

2009
Bundesministerium für Bildung und Forschung (BMBF), „HaematoSys: Systems – Biology of the Haematopoetic System and Related Neoplasias”

2009
Apogenix, Heidelberg, “Analysis of APG101 for its effect on the migration and invasion of tumor cells”

2010
Grant Support of the University of Heidelberg Foundation, “Role of specific microRNAs in EMT”

2011
German-Israeli Project Cooperation (DKFZ-MOST), “MicroRNA control of tissue invasion and inflammatory intestinal cancer”

2011
Complete Genomics, Inc., Mountain View, CA/USA, “Pilot studies on genome sequencing of resected metastases”

2011
Swiss National Fonds, Bern, Switzerland, “Defining important miRs regulating metastasis”

2011
Deutsche Krebshilfe, Bonn, “Role of specific microRNAs in the regulation of carcinoma metastasis“

2012
Wilhelm Sander-Stiftung, München, “The functional interplay between CD24, Src, miR-21, Pdcd4 and u-PAR and its impact on invasion and metastasis”

2013
6th German-Israeli Cancer Research School, Stipend for Sara Laudato (DKFZ-MOST- Project)

2014
DAAD, Bonn: “GERLS” stipend for one PhD student for 3 years

2014
Erasmus Post-Doc-Scholarship of the Erasmus Mundus Action 2 Program for Aida Hajdarpasic

2015
Erasmus Mundus Joint Master Degree (EACEA) stipend, 71000306_IMIM, for TMR/IMIM Students

2015
CSC Scholarship for Sha Guan for 24 months

2015
CSC Scholarship for Xue Cao for 24 months

2016
CSC Scholarship for Student Xinmiao Zhang for 36 months 

Ongoing grant-supported projects

2005
Alfried Krupp von Bohlen und Halbach-Stiftung, Essen (€ 1 Million); „Molecular tumor staging – translating molecular knowledge on metastasis into patient benefit“

2012
“Verification of bacterial DNA-integration into tumor DNA in colorectal           cancer”, Heidelberg Initiative of Personalized Oncology (HIPO) Grant

2013
“Genome alterations defining the metastatistically relevant cancer cell”, Heidelberg Initiative of Personalized Oncology (HIPO) Grant

2015
CSC Scholarship for Student Chan Zhou for 48 months

2016
Deutsche Krebshilfe, Bonn, „Ursachen der differenziellen Expression von microRNAs bei der Metastasierung und organspezifischen Metastasierung“

2017
MEAMEDMA Anschubfinanzierung für Mitarbeiter, Physician-Scientist Dr. Mohammed Abba

2017
Pre-Doc research stipend for Estibaliz Orue-Etxebaria Iglesias (Grant number EP_2017_1_0089) of the Basque Government in cooperation with Prof. Dr. Krypta, CICbioGune, Imperial College, London

2017
DFG, Bonn, Project number: DFG-AL-465/9-1, FAPESP- Collaboration Grant “Elucidating mechanisms underlying onset of breast cancer invasion and metastasis: deciphering the role of E3 ubiquitin Ligase Fbw7 in suppressing metastasis” for the funding of the visiting scientist Prof. Arun Trivedi, India

2017
Stipend (Young Physician Potential Development Plan by Jiangxi University, China) for Student Yu Min for 48 months    

2018
Stipend (CSC und Doctoral Study-Abroad Funding by Subei People’s Hospital, China) for Student Ping Li for 36 months  

2018
HEiKA-excellence grant (Joint program of KIT Karlsruhe and University Heidelberg), with partner Prof. H. A. Wagenknecht, KIT; Thema: “Establishing microRNA single-cell single molecule superresolution microscopy in vivo and in primary patient tissues”

Total direct funding by competitive grant support for the H. Allgayer lab: ca.  €  5.64 Mio

Doctorate Degrees to students, higher degrees to employees

2004
Denis Schewe, Dr. med. (summa cum laude)

2004
Erich Simon, Dr. med. (magna cum laude)

2005
Jörg Leupold, Dr. rer. nat. (magna cum laude)

2006
Bianca Beyer, Dr. med. (magna cum laude)

2008
Fabian Medved, Dr. med. (magna cum laude)

2008
Tobias Biller, Dr. med. (magna cum laude)

2008
Gabriele Maurer, Dr. med. (summa cum laude)

2009
Irfan Asangani, Dr. sc. hum. (summa cum laude)

2009
Giridhar Mudduluru, Dr. sc. hum. (summa cum laude)

2010
Kabeer Rasheed, Dr. sc. hum. (magna cum laude)

2010
Daniel Bürgy, Dr. med. (summa cum laude)

2011
Tina Fuchs, Dr. med. (magna cum laude)

2012
Nitin Patil, Dr. sc. hum. (summa cum laude)

2012
Alexandra Körner, Dr. sc. hum. (magna cum laude)

2013
Doreen Heckmann, Dr. sc. hum. (summa cum laude)

2013
Mohammed Abba, Dr. sc. hum., PhD (summa cum laude)

2013
Julia Rotert, Dr. med. (magna cum laude)

2013
Dr. Giridhar Mudduluru, Habilitation (Associate Professor)

2014
Jonahunata G. W. Nesson, Dr. sc. hum. (cum laude)

2014
Santoshi Muppala, Dr. sc. hum. (magna cum laude)

2016
Sara Laudato Dr. sc. hum., PhD (magna cum laude)

2018
Guan Sha, Dr. sc. hum., PhD (cum laude)

Further Activities in the scientific community

  • Associate Editor, International Journal of Cancer (since 2008), Molecular Oncology (since 2019)
  • Editor-in-Chief, Springer Nature Book Series “Recent Results in Cancer “ (since 2019)
  • Editorial Board, Advances in Medical Sciences, Journal of Cellular and Molecular Medicine, Frontiers in Molecular and Cellular Oncology, The Open Surgical Oncology Journal, Frontiers in Pharmacology, Fokus Onkologie, Translational Gastrointestinal Cancer, PEER J, RNA Biology, Journal of Cancer Metastasis and Treatment, Nature Scientific Reports.
  • EACR Council Member as Representative of Germany (since 2007), Member of the Communication Committee (since 2007), EACR Ambassador (since 2012), Member of EACR Conference Series Committee (since 2019)
  • Reviewer for scientific journals: Clinical Cancer Research, Oncogene, Cancer Research, Oncology, Nature Communications, Molecular Cancer, Molecular and Cellular Biology (MCB), International Journal of Colorectal Disease, Gastroenterology, British Journal of Cancer, PLOS ONE, Cancer Letters, World Journal of Clinical Oncology, The Open Surgical Oncology Journal, Nucleic Acids Research, FEBS Journal, APMIS, Journal of Cellular and Molecular Medicine, Frontiers in Molecular and Cellular Oncology, Methods in Enzymology, European Journal of Surgical Research, Carcinogenesis, Cancer Genetics, Molecular Cancer Research, Molecular Cancer Therapeutics, Open Access Publishing London (OAPL) Ethics Committee, Naunyn-Schmiedeberg’s Archives of Pharmacology, Molecular & Cellular Oncology, Molecular Oncology, Journal of Cancer Biology and Treatment (CBT), Experimental Cell Research, Annals of Oncology, Amino Acids, Scientific Reports, Breast Cancer Research, Oncotarget, Journal of Cellular and Molecular Medicine, Reviewer for the European Cancer Congress (ECCO 18 – ESMO 40).
  • Reviewer for funding agencies: Wilhelm Sander Foundation, Deutsche Krebshilfe (German Cancer Aid), Scientific Reviewer for the European Community (Vice Chair of EU Life Sciences Review 2008), German Israeli Foundation for Scientific Research and Development, Deutsche Forschungsgemeinschaft (DFG), Alexander-von-Humboldt Foundation, Scientific Selection Committee for the King Faisal International Prize, Riyadh/Saudi Arabia, Reviewer for the Swedish Academy of Sciences, Stockholm/Sweden, Association for International Cancer Research (AICR), Institut National du Cancer, France; Research Council for Biosciences, Academy of Finland.
  • Open Access Publishing London (OAPL) Ethics Committee (since 2013)
  • Member of the Award Selection Committee, Karl Heinz Beckurts-Stiftung, Garching (since 2013)
  • Founder of the international meeting series “Molecular Staging of Cancer” (held since 2001)
  • Chair of the Fellows of the Ingrid-zu-Solms Foundation for excellent Women in Research, Medicine and Culture, Frankfurt/Main (since 2007)
  • MD Anderson Cancer Center – DKFZ Institutional Sister Alliance (since 2007, HA supported initiation, continuous activities)
  • Visiting Professor, Medical University of Bialystok, since 2013
  • AACR Surgical Oncology Task Force, Member upon personal invitation by Dr. Margaret Foti, since 2013 (Heads: Dr. Monica Morrow, Sloan Kettering Cancer Center, Dr. Margaret Foti, AACR-CEO)
  • Member, International Advisory Committee, 7th International Conference on the Tumor Microenvironment: Progression, Therapy & Prevention, Tel Aviv, Israel, Oct 2015
  • Member, Selection Committee of the Mildred Scheel Lectureship (Deutsche Krebshilfe, Bonn, Germany)
  • Member upon personal invitation by Dr. Rolf Dobelli: WORLD.MINDS, „An invitation-only community of 1000 high-caliber individuals who have made proven contributions in science, the arts and business“ (citation from the invitation letter for the Annual Meeting 2018 in Zurich); since 2014.
  • EORTC Pathobiology Group, since 2007
  • EORTC Translational Research Advisory Committee (EORTC-TRAC; chair: Emilie Varin), since 2016
  • Main and Faculty Coordinator for establishment of new Code of Conduct (“Dachleitbild”) for University Medicine Mannheim (UMM) of University Heidelberg, with Leadership and coordinative function for whole UMM (ca. 6000 employees)
  • Opponent at International PhD Defenses, e.g. Department of Translational Medicine, Malmö/Lund University, or Finsen Laboratory, Kopenhagen, Denmark
  • Advisory Board, PEKKIP Oncology Alliance AG, since 2016
  • Member, Program Committee, Annual Meeting of the AACR 2017
  • Member, International Advisory Committee, 8th International Conference on Tumor Microenvironment: Progression, Therapy & Prevention, Lisbon, Portugal, June 2018

Kontextspalte

Prof. Dr. med. Heike Allgayer

Full Professor and Director
Dept. of Experimental Surgery – Cancer Metastasis

Medical Faculty Mannheim,
Heidelberg University
Ludolf-Krehl-Straße 13-17
68167 Mannheim

Telefon +49 (0)621/383-71630, -71635 or -71406
Fax +49 (0)621/383-71631
heike.allgayer@remove-this.medma.uni-heidelberg.de